Clinical trials: Discontinuation
Non-Small Cell Lung Cancer
A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)
This is a randomized discontinuation study of ridaforolimus in patients with advanced NSCLC who have failed at least 1 but no more than 3 prior treatment regimens and who have KRAS mutant lung cancer.
- Trial name
- NCT00818675
- Testing
- Lead-In Ridaforolimus, Comparator: Blinded Ridaforolimus
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in treating patients with recurrent or metastatic renal cell cancer.
- Trial name
- NCT00502307
- Testing
- Tivozanib (AV-951)
- Where
- 26 sites in India, Russia and 1 more
- Volunteers
- 272 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Major Depressive Disorder
Major Depressive Disorder Study In Adults
A study to obtain safety and tolerability data
- Trial name
- NCT00049972
- Testing
- paroxetine CR
- Where
- 71 sites in United States
- Volunteers
- 646 people
- Sponsor
- GlaxoSmithKline
Fibromyalgia
Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia
The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple…
- Trial name
- NCT01014585
- Testing
- Milnacipran
- Where
- 58 sites in United States
- Volunteers
- 340 people
- Sponsor
- Forest Laboratories
Cancer Cachexia
Exploratory Trial of SAT-003 in Cancer Cachexia Patients With Discontinued Chemotherapy
This clinical trial aims to evaluate the feasibility of 'SAT-003' as well as its exploratory safety and efficacy in patients with cancer cachexia who have been diagnosed with solid tumors and have discontinued anticancer…
- Trial name
- NCT06476197
- Testing
- SAT-003
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- S-Alpha Therapeutics, Inc.
Severe Hemophilia A
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
The purpose of the study is to learn about safety, how the body processes marstacimab and how it works in patients with severe hemophilia A without inhibitors.
- Trial name
- NCT06703606
- Testing
- MARSTACIMAB
- Where
- 10 sites in United States, India and 1 more
- Volunteers
- 15 people
- Sponsor
- Pfizer
Chronic Phase Chronic Myeloid Leukemia
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained…
- Trial name
- DASFREE (NCT01850004)
- Testing
- Dasatinib
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb
HCV Infection
A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
- Trial name
- NCT00726882
- Testing
- Blood sample collection only, ABT-333
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Multiple Sclerosis
Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis
Non-adherence to the treatment regimen is a common problem associated with injectable drugs (e.g. Betaferon) that are used in multiple sclerosis patients.
- Trial name
- BREAK (NCT01184833)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- Poland
- Volunteers
- 852 people
- Sponsor
- Bayer
Myalgia, Hypercholesterolemia
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
The purpose of this study is to assess the incidence of statin-associated myalgia (SAM) with treatment with PPD10558 versus atorvastatin in patients previously intolerant to statins.
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT01279590
- Testing
- PPD10558, Atorvastatin
- Where
- 67 sites in United States
- Volunteers
- 282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Psychosis
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
This is a safety study evaluating the subjects who participated in previous Organon trials of the drug Org 24448. Patients will undergo a Screening visit, 1 or 2 Evaluation visits, and a possible Follow-Up period.
- Trial name
- NCT00780585
- Testing
- SCH 900460
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B, Chronic
A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment
The purpose of this study is to assess the incidence of participants who reach hepatitis B surface antigen (HBsAg) seroclearance after discontinuing nucleos(t)ide analog (NA) therapy in participants with HBsAg less than or equal…
- Trial name
- SALMONS (NCT05550519)
- Testing
- Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF)
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Hepatitis C Virus Infection
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
This is a follow-up study with no treatment and only samples being collected.
- Trial name
- NCT00872196
- Testing
- ABT-072
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Osteoporosis
CR9112792, a Follow-up of Study CR9108963
The purpose of this study is to determine whether bone mineral density has increased in a subgroup of postmenopausal osteoporotic women from study CR9108963, between 6 and 12 months following cessation of ronacaleret therapy.
- Trial name
- NCT00891553
- Testing
- DXA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 171 people
- Sponsor
- GlaxoSmithKline
Solid Tumor, Hematological Malignancies
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
This is an open-label, extension protocol designed to allow patients to continue to receive belinostat treatment after they have completed the protocol-specified assessments and procedures in a Spectrum sponsored belinostat study…
- Trial name
- NCT04184869
- Testing
- Belinostat, Atazanavir
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Acrotech Biopharma Inc.
Obesity
RESCUE: Discontinuation of GLP-1
This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.
- Trial name
- NCT07190794
- Testing
- OverStitch™ or OverStitch NXT™, Lifestyle Modification
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Boston Scientific Corporation
Alzheimer's Disease
A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)
This study is an observational study conducted prospectively under routine clinical setting for 1 year with about 700 patients diagnosed as Alzheimer's disease who will be treated by donepezil (Aricept) as monotherapy.
- Trial name
- ADOS (NCT02262975)
- Where
- 26 sites in China, Philippines and 4 more
- Volunteers
- 532 people
- Sponsor
- Eisai Korea Inc.
Infection, Bacterial Infection
Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection
The purpose of this study is to test whether a U.S. Food and Drug Administration (FDA) approved laboratory test (PCT Kryptor) can help doctors make better decisions on the need for antibiotic therapy in ICU patients with…
- Conditions
- Infection, Bacterial Infection, Sepsis
- Trial name
- NCT00407147
- Testing
- Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brahms AG